Aim: Liver biopsy is the gold standard for assessing liver fibrosis (LF) after liver transplantation (LT), but its invasiveness limits its utility. This study aimed to evaluate the usefulness of liver stiffness measurement (LSM) using acoustic radiation force impulse (ARFI) imaging to assess LF after LT.
INTRODUCTION

L
IVER TRANSPLANTATION (LT) has become the treatment of choice for end-stage liver diseases worldwide. 1 Although short-and long-term results have been improved with the development of operative techniques and perioperative management, 2 they still leave room for further improvement. 3 Graft fibrosis is a serious condition after LT, which can cause graft dysfunction leading to graft loss and retransplantation. Early recognition and treatment intervention are of paramount importance in improving long-term prognosis of LT patients.
Percutaneous liver biopsy has been the gold standard for the assessment of graft condition, including acute cellular rejection and graft fibrosis, in the post-transplant setting. 4 Histopathological examination of biopsy specimens can reveal not only rejection and fibrosis of graft liver but also the recurrence of primary diseases such as viral hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. [5] [6] [7] [8] However, liver biopsy is associated with poor compliance owing to its invasiveness and possible complications. Less invasive methods are strongly desired, especially for long-term follow-up. 9 Recently, liver stiffness measurement (LSM) has been developed as a non-invasive method for assessing liver fibrosis (LF). 10, 11 Previous studies reported that LSM using magnetic resonance elastography and ultrasound-based elastography methods, such as acoustic radiation force impulse (ARFI) and FibroScan (Echosens, Paris, France), were useful for evaluating LF. [12] [13] [14] [15] [16] [17] [18] [19] [20] In addition, the usefulness of LSM in predicting development of clinical manifestations of liver cirrhosis such as esophageal varices, portal hypertension, ascites, and hepatocellular carcinoma has been reported in several studies. 21, 22 Our previous report showed that LSM by ARFI was useful for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma. 23 The utility of FibroScan for the assessment of graft fibrosis after LT has been reported by several studies, [24] [25] [26] [27] however, the utility of ARFI has been evaluated by only a few studies involving small number of patients with inconclusive results. [28] [29] [30] [31] [32] This study is the largest post-LT cohort study for assessment of LSM using ARFI imaging. The aim of this study was to evaluate the usefulness of LSM by ARFI imaging for the evaluation of graft conditions such as fibrosis.
METHODS
Patients W E PROSPECTIVELY COLLECTED and analyzed the clinicopathological data of 278 patients who underwent liver biopsies for post-transplant assessment of graft liver at Kyoto University Hospital (Kyoto, Japan) between September 2013 and January 2017. Written informed consent was obtained from all patients after liver biopsy.
The study protocol was approved by the Ethics Committee of the Kyoto University Graduate School and Faculty of Medicine (approval code: E1992) and was registered with the University Hospital Medical Information Network (unique trial number: UMIN R000028296).
Data collection
Clinicopathological data including sex, age, body mass index (BMI), primary disease, splenectomy on LT, blood compatibility, reason for biopsy, and interval between biopsy and LT were collected.
All patients underwent blood examinations, including liver function tests (measurement of platelet count, international normalized ratio of prothrombin time [PT-INR], alanine transaminase level, γ-glutamyl transpeptidase level, total bilirubin [T-Bil] level, total bile acid level, total protein [TP] level, and albumin [ALB] level and the levels of fibrosis markers such as hyaluronic acid and type 4 collagen), on the same day as liver biopsy. Aspartate transaminase to platelet ratio index (APRI) and Fibrosis-4 (FIB-4) index were calculated according to the equations previously reported. [33] [34] [35] Liver biopsy and histological assessment Liver biopsy examination was undertaken when clinically indicated (e.g. when rejection was suspected) or at designated intervals (so-called protocol biopsy), with informed consent. An 18-G biopsy needle was routinely used, and the minimal acceptable size of liver biopsy specimens was 15 mm. Biopsy specimens were fixed in formalin, embedded in paraffin, and stained with hematoxylin-eosin and Masson's trichrome. Necroinflammatory activity (A0-A3) and fibrosis stage (F0-F4) were assessed according to METAVIR scores. 36 
Liver stiffness measurement
Liver stiffness was evaluated using ACUSON S2000 (Mochida Siemens Medical Systems, Tokyo, Japan) as previously reported. 37 In the ARFI, the value of tissue stiffness in a region of interest is expressed as the shear wave velocity (Vs) in meters per second (m/s). The LSM was carried out on the same day as the biopsy. The examined patients were laid in the supine position. The region of interest (fixed-dimension 1 × 0.5-cm box) was chosen in the lobe from the intercostal space or epigastric scan at a depth of 4-6 cm from the surface and free of large vascular structures. The Vs values were measured 10 times in every patient, and the mean value in m/s was calculated. Valid ARFI measurements were obtained in all patients. The operators were blinded to the clinical data.
Statistical analysis
All statistical analyses were carried out using SAS software (JMP 12.0.; SAS Institute, Cary, NC, USA). Continuous variables were expressed as mean values ± standard deviation or medians with ranges and compared using Student's ttest, the Kruskal-Wallis test, or Wilcoxon's rank-sum test. Categorical variables were compared using the χ 2 -test or Fisher's exact test as appropriate. The diagnostic significance of Vs and laboratory tests for fibrosis scores ≥F2 were evaluated in multivariable analyses. The variables included in the analyses were selected based on the results of univariate analysis (P < 0.05). The diagnostic performance for fibrosis scores ≥F2 and ≥F3 was assessed using receiver operating characteristic (ROC) analysis, and the area under the ROC curve (AUROC) was calculated. The optimal cutoff values were determined to maximize the sum of sensitivity and specificity. The ROC curves were compared using the DeLong test. A P-value of <0.05 was considered statistically significant. (Fig. 1) . The median Vs appeared to be weakly correlated with METAVIR activity score in A0-A2, but not in A3, presumably because of insufficient sample number. The Vs was not correlated with rejection activity index score. 38 The diagnostic performance of Vs and laboratory tests for LF stage was analyzed ( Table 2 ). The Vs had higher AUROC than any laboratory tests for the prediction of both ≥F2 (AUROC 0.77; 95% confidence interval [CI], 0.70-0.82) and ≥F3 fibrosis (AUROC 0.85; 95% CI, 0.77-0.91). The cut-off values for ≥F2 and ≥F3 were 1.31 m/s and 1.53 m/s, respectively, and the sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio for ≥F2 were 89.4%, 53.3%, 37.3%, 94.2%, 1.91, and 0.20, respectively, and those for ≥F3 were 92.9%, 69.7%, 14.0%, 99.5%, 3.07, and 0.10, respectively (Table 3) .
Model for prediction of ≥F2 fibrosis
The univariable logistic regression analysis of each variable and the multivariable stepwise selection in predicting ≥F2 were carried out (Table 4 ). Significant differences were observed in Vs (P < 0.001), PT-INR (P = 0.016), T-Bil level (P = 0.009), total bile acid level (P < 0.001), TP level (P = 0.004), ALB level (P = 0.027), hyaluronic acid level (P = 0.037), and type 4 collagen level (P = 0.006) between the patients with and without ≥F2 in the univariable analysis. Shear wave velocity (odds ratio [OR] 2.43; 95% CI, 1.63-3.79; P < 0.001), PT-INR (OR 1.93; 95% CI, 1.20-3.19; P = 0.006), and TP level (OR 1.66; 95% CI, 1.11-2.56; P = 0.013) remained significant in the multivariate analysis.
The ≥F2 risk index incorporating these three parameters was generated as follows: 
The AUROC of the F2 ≤ risk index was 0.79 (95% CI, 0.72-0.84). However, the predictive power of this risk index was not significantly better than that of Vs alone (P = 0.359) (Fig. 2) .
Comparison of diagnostic accuracy for ≥F2 in various subpopulations
The serum markers can be affected by various factors such as primary disease and presence of rejection, which might have resulted in inferior diagnostic performance of laboratory tests in our heterogeneous study cohort. The Figure 1 Correlation between shear wave velocity (Vs) and METAVIR fibrosis score in 278 Japanese patients with previous liver transplantation. Differences between the abutting stages were evaluated using the Wilcoxon rank-sum test. *P < 0.05, **P < 0.01, ****P < 0.0001. Optimal cut-off values were determined to maximize the sum of sensitivity and specificity. NLR, negative likelihood ratio; NVP, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value. diagnostic performance for ≥F2 was compared between Vs and laboratory tests in various subpopulations, which are expected to be more homogeneous than the entire cohort.
In the subpopulation where the primary disease was biliary atresia, the diagnostic power of laboratory tests was scarcely affected compared with the whole cohort, revealing a statistically significant difference from that of Vs in most of the serum markers (Table 5 ). In the HCV cohort, in contrast, several serum markers including PT-INR, T-Bil, TP, ALB, and hyaluronic acid yielded improved diagnostic performance compared with the entire cohort, although Vs still showed a higher AUROC value than any serum parameters. The same trend was observed also in the splenectomized cohort ( Table 6 ).
Impact of scanning site on diagnostic performance of Vs
We analyzed the variation (Vs standard deviation/Vs mean) of Vs to evaluate the reproducibility of ARFI examination. The variation of epigastric scan (n = 71) was significantly larger than that of intercostal scan (n = 207) in the evaluation of liver stiffness (P < 0.001, 0.11 ± 0.005, 0.08 ± 0.003, respectively), indicating better reproducibility of LSM in intercostal scan than in epigastric scan. As a result, the AUROC of Vs in intercostal scan was significantly better than that in epigastric scan for prediction of ≥F2 fibrosis (P = 0.046; AUROC 0.80, 95% CI, 0.72-0.86; AUROC 0.63, 95% CI, 0.47-0.77, respectively) (Fig. 3) . Reflecting this, Vs predicted ≥F2 more accurately in the right lobe graft than in the lateral segment and left lobe graft (P = 0.04; AUROC 0.83, 95% CI, 0.70-0.91; AUROC 0.67, 95% CI, 0.59-0.77).
DISCUSSION
C URRENTLY, LIVER BIOPSY is the gold standard for the evaluation of LF. However, major complications were reported to occur in 0.6%, and mortality rate was 0.09% in a systematic review. 9 Additionally, Bedossa et al. reported that diagnostic accuracy was only 65% with biopsy specimens with 15-mm length and 75% even with 25-mm length, indicating suboptimal accuracy of needle biopsy due to sampling variability. 39 The demand for less invasive and more accurate diagnostic tool for assessing LF is continually growing.
The usefulness of serum markers or composite markers as non-invasive methods for the evaluation of LF has been reported. Benlloch et al. and Cross et al. reported the usefulness of the original formula of predicting fibrosis using Table 5 Receiver operating characteristic analysis of markers in predicting ≥F2 fibrosis in Japanese liver transplant recipients categorized according to primary disease 42,43 Additionally, Carrion et al. reported that direct fibrosis markers such as tissue inhibitor of metalloproteinase-1, amino-terminal propeptide of type III procollagen, and hyaluronic acid were better than APRI or Benlloch et al.'s original formula in predicting fibrosis in HCV patients after LT. 44 However, these studies Table 6 Receiver operating characteristic analysis of markers in predicting ≥F2 fibrosis in Japanese liver transplant recipients categorized according to splenectomy DeLong test (vs. shear wave velocity [Vs]): *P < 0.05. **P < 0.01. ***P < 0.001. ****P < 0.0001. APRI, aspartate transaminase to platelet ratio index; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; FIB-4, Fibrosis-4; PT-INR, international normalized ratio of prothrombin time; Vs, shear wave velocity. Figure 3 Comparison of diagnostic ability for ≥F2 fibrosis in Japanese patients with previous liver transplantation between intercostal scan and epigastric scan. AUROC, area under the receiver operating characteristic curve; CI, confidence interval.
indicated that the diagnostic performance of serum markers were not reproducible in the studies other than the original one and questioned the validity in the external cohort. Previous studies reported that FibroScan was useful for evaluation of LF, [13] [14] [15] and a meta-analysis has shown that its efficacy for evaluation of LF was equivalent to composite markers in non-transplant patients. 45 Recently, several studies have reported the usefulness of ARFI as a device to evaluate LF [16] [17] [18] and a meta-analysis showed ARFI is as useful as FibroScan in non-transplant patients. 46 However, in liver transplant patients, several studies reported that FibroScan is more useful than serum or composite markers in evaluation of LF. [24] [25] [26] [27] Accordingly, ARFI is expected to be better than serum markers and composite markers for the evaluation of fibrosis in liver transplant patients. However, only a few small studies have been published that assessed the efficacy of ARFI in the post-transplant setting, and these results are inconclusive, probably because of a small sample size. [28] [29] [30] [31] [32] Additionally, measurement using FibroScan, which is based on the M-mode and A-mode imaging of ultrasonography, is not a real-time procedure. Its potential limitation is that measurement is difficult in obese patients or patients with ascites, and it is affected by the operator's experience. 47 In contrast, ARFI technology, which is a simple real-time procedure based on B-mode imaging, makes it possible to observe the region of interest, adapt measurement depth according to the skin to liver capsule distance, and measure slim and obese patients as well as patients with ascites. 48 A previous study reported that ARFI is better than FibroScan for patients with ascites, higher BMI, and longer abdominal perimeter. 49 Therefore, ARFI might be more useful than FibroScan, and we examined the usefulness of ARFI in evaluating fibrosis of a transplanted liver.
We confirmed that Vs, the liver stiffness value measured by ARFI, was significantly correlated with the stage of LF. We found that Vs was better than any serum or composite marker for the diagnosis of significant (≥F2) and advanced (≥F3) fibrosis. When the cut-off values were 1.31 and 1.53, Vs had good negative predictive value and negative likelihood ratio in predicting ≥F2 and ≥F3, respectively, indicating that LSM by ARFI is useful for identifying patients who are unlikely to have significant fibrosis, and can effectively rule out such patients to reduce the frequency of nonessential liver biopsies.
A multivariable analysis was further carried out, and a model for predicting significant fibrosis (≥F2) was built. Selection of TP, not ALB, presumably reflects increasing globulin fraction in fibrotic patients 50, 51 and is concordant with Benlloch et al.'s study that identified the ALB/TP ratio as a predictive factor for significant fibrosis. 40 The obtained equation of this model, the Vs-PT-INR-TP index, had good diagnostic accuracy for ≥F2 fibrosis (AUROC 0.79). However, even Vs alone had an AUROC of 0.77, without significant difference from that of the Vs-PT-INR-TP index, suggesting that the addition of laboratory tests to Vs adds little diagnostic information regarding LF in the post-transplant setting.
In non-transplant settings, several biomarkers and composite markers have been shown to be useful for the prediction of LF. [33] [34] [35] The present study showed that the usefulness of laboratory tests for diagnosis of graft fibrosis after LT was limited, as indicated by low AUROC values of these markers. The reason for the discrepant efficacy of laboratory tests for the estimation of LF between nontransplant patients and post-transplant patients is a matter of interest. In transplant recipients, laboratory tests can be influenced by various factors other than the progression of fibrosis. These include rejection, recurrence of primary disease, biliary complications, presence of the spleen, and immunosuppressants, and they might affect the diagnostic performance of blood tests. For example, rejection could increase aspartate transaminase level irrespective of LF and affect APRI, which incorporates aspartate transaminase into its formula. In contrast, liver stiffness is barely influenced by conditions other than LF, as indicated by weaker correlations with the activity score or rejection activity index score than with the fibrosis score. Notably, the presence of the spleen could affect various laboratory tests such as measurement of platelet count and T-Bil, as reported by previous studies showing splenectomy increased platelet count and T-Bil level. [52] [53] [54] [55] This is in agreement with our finding that diagnostic performance of laboratory tests was improved in splenectomized patients. The present study emphasizes the usefulness of LSM for diagnosis of graft fibrosis as Vs is consistently reliable in predicting graft fibrosis without being affected by patient background.
Diagnosis of LF based on ARFI does have several limitations. First, LSM with epigastric scan was less reproducible than that with intercostal scan, resulting in less reliable diagnostic performance. A previous study reported that ARFI examination can be carried out more accurately for the right lobe than that for the left lobe in evaluating fibrosis. 56 Toshima et al. similarly reported that the AUROC for diagnosing LF by the Vs of intercostal scan for the right lobe was significantly higher than for that of epigastric scan for the left lobe, and the standard deviation of the measured values for the right lobe was significantly lower than that of the left lobe. 57 The reason for these differences was assumed that the epigastric scan for the left lobe surrounded by the diaphragm, stomach, and aorta might be influenced by respiratory fluctuations, the presence of food in the stomach, and the pulsation of the aorta. Hence, as the accuracy of ARFI examination might be influenced by not only the scanning site, but also the scanning lobe, we have to keep in mind that LSM by ARFI should be undertaken in the intercostal scan if possible and that the diagnostic reliability is reduced when ARFI is undertaken in the epigastric scan due to an inadequate window for an intercostal scan. Second, ARFI did not show good specificity or positive predictive value in evaluation for ≥F2 or ≥F3. Therefore, we have to be aware that false positives are frequently encountered in the evaluation of severe fibrosis using ARFI imaging.
In conclusion, LSM by ARFI imaging is very useful in predicting graft fibrosis after LT, regardless of the type of primary disease or patient background and can minimize the frequency of non-essential liver biopsies by detecting patients who are unlikely to have significant fibrosis after LT.
